Back to today’s briefing

Story perspectives

Novo Nordisk launches weekly Awiqli insulin in India.

7/10/2026

35 2 Full Breakdown

Summary

Story summary

Novo Nordisk launched Awiqli, the first once-weekly basal insulin, in India on July 10, 2026.
Awiqli cuts injections from 365 to 52 per year and costs INR 261 weekly.
The ONWARDS trial of over 4,000 adults showed Awiqli lowered HbA1c more than daily insulin glargine.
The UK MHRA approved Wegovy for MASH, a liver disease with moderate-to-advanced fibrosis, while NICE has not ruled on NHS reimbursement.

1 of 1

Story summary

Novo Nordisk launched Awiqli, the first once-weekly basal insulin, in India on July 10, 2026.
Awiqli cuts injections from 365 to 52 per year and costs INR 261 weekly.
The ONWARDS trial of over 4,000 adults showed Awiqli lowered HbA1c more than daily insulin glargine.
The UK MHRA approved Wegovy for MASH, a liver disease with moderate-to-advanced fibrosis, while NICE has not ruled on NHS reimbursement.